Literature DB >> 8254836

Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis.

A Horwich1, A Norman, C Fisher, W F Hendry, J Nicholls, D P Dearnaley.   

Abstract

Between 1979 and 1989, 122 patients with clinical stage II testicular nonseminoma were treated with primary platinum-based combination chemotherapy following orchiectomy. Of the patients 58 had Royal Marsden Hospital stage IIA (nodes less than 2 cm. in diameter) and the other 64 had stage IIB (nodes 2 to 5 cm. diameter) disease. With a median followup after chemotherapy of 5.5 years, 118 patients (97%) were disease-free. Two patients died of progressive germ cell tumors, 1 of bleomycin toxicity and 1 of coincidental disease. The 5-year actuarial survival probability was 95% (95% confidence intervals 91 to 99%) and the 5-year failure-free survival probability was 92% (95% confidence intervals 88 to 97%). Tumor substage was not predictive of relapse but did indicate the probability of lymphadenectomy for a post-chemotherapy residual mass since this was performed in 17% of the patients with stage IIA disease and 39% with stage IIB disease (p < 0.05). Resected specimens contained mature teratoma (29), necrosis alone (5) or embryonal carcinoma (1). We conclude that for these clinical stages primary chemotherapy was as effective as primary lymph node dissection and a major operation was avoided in 68% of the cases.

Entities:  

Mesh:

Year:  1994        PMID: 8254836     DOI: 10.1016/s0022-5347(17)34874-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Metastatic testicular germ cell tumour: the role of salvage surgery.

Authors:  K Suzuki; K Kurokawa; T Suzuki; S Jinbo; M Kobayashi; K Imai; H Yamanaka
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

2.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

Review 3.  Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors.

Authors:  Salim K Cheriyan; Marilin Nicholson; Ahmet M Aydin; Mounsif Azizi; Charles C Peyton; Wade J Sexton; Scott M Gilbert
Journal:  Transl Androl Urol       Date:  2020-01

Review 4.  Early-stage testis cancer.

Authors:  R S Foster
Journal:  Curr Treat Options Oncol       Date:  2001-10

5.  Urological second malignant neoplasms in testicular nonseminoma survivors: a population-based analysis.

Authors:  Hao Li; Chenxing Zhu; Jiapei Wu; Yuchen Ma; Xi Jin; Xin Wei; Kunjie Wang; Hong Li
Journal:  Int Urol Nephrol       Date:  2020-10-14       Impact factor: 2.370

6.  Fertility considerations in nerve-sparing retroperitoneal lymph-node dissection.

Authors:  R S Foster; A McNulty; L R Rubin; R Bennett; R G Rowland; G W Sledge; R Bihrle; J P Donohue
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

7.  Stage II nonseminomatous germ-cell testicular tumors--the Indiana experience and risk-benefit analysis.

Authors:  R S Foster; R Bihrle; J S Little; R G Rowland; J P Donohue
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.